| 12240869 |
Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro |
2025-03-04 |
|
| 11918592 |
Inhibitors of cyclin dependent kinase 7 (CDK7) |
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras +2 more |
2024-03-05 |
$4,223,000 |
| 11040957 |
Heteroaromatic compounds useful for the treatment of proliferative diseases |
Stephane Ciblat, Patrick Deroy, Nathanael S. Gray, Melissa Leblanc, Jason J. Marineau +10 more |
2021-06-22 |
|
| 10906889 |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
Nathanael S. Gray, Tinghu Zhang, Stephane Ciblat, Melissa Leblanc, Jason J. Marineau +8 more |
2021-02-02 |
|
| 10738067 |
Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro |
2020-08-11 |
$11,399,000 |
| 10519135 |
Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Kevin Sprott, Jason J. Marineau, Darby Schmidt, Stephane Ciblat, M. Arshad Siddiqui +8 more |
2019-12-31 |
$6,154,000 |
| 10329276 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2019-06-25 |
$501,050,000 |
| 10106526 |
Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Kevin Sprott, Jason J. Marineau, Darby Schmidt, Stephane Ciblat, M. Arshad Siddiqui +8 more |
2018-10-23 |
$4,194,000 |
| 10059690 |
Inhibitors of cyclin-dependent kinase 7 (CDK7) |
Stephane Ciblat, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li +8 more |
2018-08-28 |
$7,271,000 |
| 10047070 |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
Nathanael S. Gray, Tinghu Zhang, Stephane Ciblat, Melissa Leblanc, Jason J. Marineau +8 more |
2018-08-14 |
|
| 9873681 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2018-01-23 |
$357,551,000 |
| 9539250 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2017-01-10 |
$139,904,000 |
| 8969569 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2015-03-03 |
$62,912,000 |
| 8841455 |
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors |
Mark Laurence Boys, Robert Kirk DeLisle, D. David Hennings, April L. Kennedy, Fredrik P. Marmsater +7 more |
2014-09-23 |
$3,108,000 |
| 8648093 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2014-02-11 |
$80,096,000 |
| 8273892 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2012-09-25 |
$31,029,000 |
| 8252813 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2012-08-28 |
$29,684,000 |
| 7728143 |
Salt and crystalline forms thereof of a drug |
Geoff G. Zhang, David M. Barnes, Rodger F. Henry |
2010-06-01 |
$48,024,000 |
| 7592466 |
Ureas having antiangiogenic activity |
Fortuna Haviv, Daryl Sauer |
2009-09-22 |
$133,275,000 |
| 7169888 |
Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
Fortuna Haviv |
2007-01-30 |
$37,280,000 |
| 7122625 |
Hexa-, hepta-, and octapeptides having antiangiogenic activity |
Fortuna Haviv |
2006-10-17 |
$164,996,000 |
| 7067490 |
Hepta-, Octa-and nonapeptides having antiangiogenic activity |
Fortuna Haviv |
2006-06-27 |
$96,655,000 |
| 7037897 |
TRI-, TETRA-, and penta-peptides having antiangiogenic activity |
Fortuna Haviv |
2006-05-02 |
$56,784,000 |
| 7001984 |
Di-, tri-, and tetra-peptides having antiangiogenic activity |
Fortuna Haviv |
2006-02-21 |
$42,599,000 |
| 6777535 |
N-alkylated peptides having antiangiogenic activity |
Fortuna Haviv, Jack Henkin, Douglas M. Kalvin |
2004-08-17 |
$57,458,000 |
